Literature DB >> 9926234

World Health Organization Classification of lymphomas: a work in progress.

E S Jaffe1, N L Harris, J Diebold, H K Müller-Hermelink.   

Abstract

The World Health Organization (WHO) publishes classification handbooks for all neoplastic diseases. The last WHO Classification of leukemias and lymphomas was published in 1976. Since that time, through cytogenetics and molecular biology, it has been shown that many hematopoietic neoplasms are associated with a unique genetic profile. Similarly, the development of widely available and routinely applied monoclonal antibodies has allowed the identification of a unique immunophenotypic profile for most leukemias and lymphomas. These techniques have permitted the recognition of a number of distinct disease entities, and also enhance both diagnostic accuracy and reproducibility. The WHO Classification has been developed under the joint auspices of the European Association for Hematopathology (EAHP) and the Society for Hematopathology (SH). First organized in 1995, the Steering Committee appointed 10 committees covering T-cell and B-cell lymphomas and leukemias, myeloid and histiocytic tumors. The committees were asked to develop a list of diseases within their topic area, and to establish definitions of each disease according to established criteria. The WHO Classification uses the principles of the R.E.A.L. Classification, which defines each disease according to its morphology, immunophenotype, genetic features, postulated normal counterpart, and clinical features. Morphologic and clinical variants of individual diseases are discussed in the text, and their use is optional. The proposed classification was presented at the USCAP meeting in 1997, the site of the first joint meeting of the EAHP and SH. The presentation was followed by an open forum attended by EAHP and SH members. The Steering Committee also appointed a Clinical Advisory Committee to ensure that the classification meets clinical needs, and to resolve questions of clinical significance. The proposed WHO Classification for lymphomas is similar to the R.E.A.L. Classification for lymphomas, with minor modifications and reassessment of provisional categories based on new data since 1994.

Entities:  

Mesh:

Year:  1998        PMID: 9926234     DOI: 10.1093/annonc/9.suppl_5.s25

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas.

Authors:  A Rosenwald; G Ott; S Stilgenbauer; J Kalla; M Bredt; T Katzenberger; A Greiner; M M Ott; B Gawin; H Döhner; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Vesna M Cemerikic Martinovic; Tamara K Kravic; Vladimir Z Bumbasirevic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

5.  Principles behind definitions of diseases--a criticism of the principle of disease mechanism and the development of a pragmatic alternative.

Authors:  M Severinsen
Journal:  Theor Med Bioeth       Date:  2001-08

6.  Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Authors:  Lan V Pham; Archito T Tamayo; Changping Li; William Bornmann; Waldemar Priebe; Richard J Ford
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

Review 7.  T-small cell disorders.

Authors:  E H Westin; D L Longo
Journal:  Curr Treat Options Oncol       Date:  2001-06

8.  Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate.

Authors:  Jung Julie Kang; Michael S Eaton; Yanling Ma; Oscar Streeter; Parvesh Kumar
Journal:  Rare Tumors       Date:  2010-09-30

9.  Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.

Authors:  Christine F Skibola; Paige M Bracci; Eran Halperin; Alexandra Nieters; Alan Hubbard; Randi A Paynter; Danica R Skibola; Luz Agana; Nikolaus Becker; Patrick Tressler; Matthew S Forrest; Sriram Sankararaman; Lucia Conde; Elizabeth A Holly; Martyn T Smith
Journal:  PLoS One       Date:  2008-06-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.